Stefan Duvall

Speaking & conversations

Conversations that make a technical recommendation easier to examine

01

What the restored record must still explain

Forty-minute keynote with moderated discussion · Manufacturing executives, laboratory leaders and technology sponsors

I open with a restoration exercise in which every backup job succeeded but three packages lacked the method context needed for interpretation. The session asks participants to distinguish several claims that are often compressed into a single readiness statement: information was copied, an environment was restored, an authorised person could read it and the relevant specialists could assess it for its intended purpose. I use the fictional case to show how a more precise question changes the proposed response and its cost. Participants then consider a transition in their own setting and identify the future reader, the dependencies that reader needs and the authority responsible for judging the result. The discussion does not prescribe a universal architecture or a compliance checklist. It is intended to help executive sponsors ask what the reported test actually establishes, which uses remain outside its scope and how an unresolved condition should appear in the decision. No confidential records are needed for the exercise.

02

When a supplier timetable meets an acceptance decision

Ninety-minute cross-functional workshop · Application owners, procurement leaders, quality specialists and CIO teams

This workshop follows a fictional supplier release with 180 agreed workflow scenarios, eighteen failures and a costly six-week deferral. I ask the group to examine the proposal from the perspectives of the supplier, the technical team, the operating user and the function responsible for acceptance. Each perspective brings a legitimate concern, but none should silently replace the others. Participants work through the difference between correcting a display mapping, correcting a permission boundary and deciding whether the resulting evidence supports the next release step. We discuss how to preserve the original failed tests, how to state the scope of the passing results and how to present continued-support cost without letting it determine the acceptance standard by default. The intended result is a clearer decision record, with named responsibilities and explicit qualifications. The session uses invented material and does not assess a participant's actual regulated system or provide a product-quality determination for their organisation.

03

The people hidden inside the investment schedule

Sixty-minute executive working session · Investment committees, programme sponsors and functional leaders

I explore a portfolio whose financial resources were visible but whose specialist review assumptions were not. A proposed analytics capability needed experienced people already committed to laboratory, manufacturing and quality work. Funding additional development did not remove that dependence. The session helps participants translate a milestone labelled review into the decisions, preparation and participation it actually requires. We compare a smaller technical scope, resequencing, external support and deliberate deferral, asking which option changes the constraint rather than merely changing the presentation. I also discuss the opportunity cost of waiting and why an unapproved request should not be counted as a realised saving when it is deferred. Participants leave with questions they can apply to an investment paper: whose judgement is required, what capacity exists now, what must be developed and who has agreed the competing priorities. The purpose is to make the execution case as examinable as the financial proposition, without assuming that every capacity problem has the same remedy.

04

Retiring technology without retiring the explanation

Forty-five-minute board and senior-management briefing · Directors overseeing established operations and technology renewal

An application may stop receiving new work before an enterprise can stop using it to understand historical material. I use a fictional archive-reader decision to make that distinction tangible. The discussion follows a 1,200-package sample, a retained retrieval dependency and the difference between an anticipated annual saving and the cost of a defined retention programme. I explain the questions directors can ask without becoming system designers: which uses have been examined, what remains dependent on the older capability, who owns it and what evidence would permit retirement. We also consider why a sample chosen to explore configurations should not be presented as a statistical estimate of the entire archive. The briefing is designed to improve oversight of the obligations left after a modernisation project closes. It does not advocate indefinite retention, prescribe legal retention periods or claim that a single technology arrangement will satisfy every future need of a manufacturing enterprise.

Short speaker biography

I am Stefan Duvall, a fictional European pharmaceutical CIO with thirty-two years in manufacturing and laboratory technology. I speak about preserving record meaning through change, examining supplier releases and recognising the specialist capacity behind an investment plan. My examples distinguish technical evidence from the quality and operating decisions it supports.

Standard speaker biography

I lead technology at the fictional Orvanel Therapeutics, with 144 employees and EUR68 million of authority for 2026. My career began in manufacturing systems analysis in 1994 and developed through plant informatics, laboratory applications and enterprise systems. I discuss the practical obligations that remain after a technical milestone: interpreting earlier records, supporting an older reader and obtaining the experienced review needed for change. My sessions use clearly invented cases with stated costs and limitations. I present to directors as an executive but hold no board seat. I aim to give sponsors and directors better questions about the evidence behind a technology recommendation, without substituting for quality judgement or specialist legal advice.

Extended speaker biography

I am the fictional CIO of Orvanel Therapeutics, a Lyon-headquartered manufacturer of established prescription medicines with operations in France, Belgium and the Netherlands. I lead 144 technology employees through six direct reports, supported by forty-two contractors counted separately. My 2026 authority is EUR68 million, divided between EUR44 million continuing operations and EUR24 million change. I report to the CEO and present technology matters to directors; I have not served as a director myself.

My career started at Cerlun Pharmaceuticals in September 1994, after an information systems master's degree. I joined Orvanel in plant informatics in 2002, moved into laboratory systems in 2009 and enterprise systems in 2014, and became CIO in January 2020. Those roles shaped my interest in the meaning that must survive a change of application, instrument or supplier.

In executive sessions I discuss restoration exercises, release acceptance, archive retrieval and the finite review capacity behind investment schedules. My cases retain their costs and qualifications: a successful test has a scope, an old reader can remain necessary and a deferred request is not automatically a saving. I do not provide clinical recommendations or represent technical completion as regulatory endorsement. I want participants to examine the account they would need before making their own next decision.

An invitation

Contact

I am open to a carefully scoped non-executive conversation where technology, manufacturing and evidence stewardship meet. An external role would need employer agreement, a workable twenty-one-day annual commitment and a proper examination of conflicts and appointment requirements.

Open to
  • Board appointments
  • Speaking invitations
  • Executive opportunities

office@stefanduvall.example